Division of Systems Toxicology, National Center for Toxicological Research, U.S. Food and Drug Administration
Huixiao Hong received his PhD at Nanjing University China in 1990 and completed his postdoctoral fellowship at the Maxwell Institute at Leeds University in UK. He was an Associate Professor at Nanjing University from 1992 to 1995 where he investigated computerassisted molecular design From 1995 to1998 he worked at National Cancer Institute at National Institutes of Health as a Visiting Scientist. He discovered and designed more than 60 potent HIV integrase inhibitors and cyclooxygenase COX inhibitors. He also identified a mononucleotidebinding site in HIV integrase and elucidated the stereoselective binding mode of ibuprofen in COX1. From 1998 to 2000 he held a Research Scientist position in Sumitomo Chemical Company in Japan. He joined the information technology and scientific computing contract under ZTech at FDA’s NCTR in 2000 and served as the computational science group manager from 2002 to 2007. He became a senior scientist at the US FDA’s National Center for Toxicological Research in 2007. He published more than 80 scientific papers and served as an Executive Editor or a member of Editorial Board of 9 peerreviewed journals and as a reviewer of more than 20 peerreviewed journals in the area of pharmacogenomics proteomics bioinformatics and chemoinformatics.
Genome-wide association studies (GWAS): baseline practices for analyzing GWAS data, technical robustness of genotyping technology, sources of spurious associations, batch effects in GWAS; Proteomics: quality control and quality assessment of proteomics data, biomarkers for detecting hepatotoxicity, prediction protein function from protein sequences; Genomics: development of classifiers of diagnosis and prognosis based on gene expression profiles.